Bupropion for the Treatment of Apathy in Alzheimer's Dementia

Apathy in Dementia Clinical Trial

— APA-AD  

Official title:

A 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Bupropion for the Treatment of Apathy in Alzheimer's Dementia(Apa-AD)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01047254
• Other study ID #: 2007-005352-17
• Status: Completed
• Phase: Phase 3
• First received: January 11, 2010
• Last updated: May 8, 2017
• Start date: January 2010
• Est. completion date: July 2014

Study information

• Verified date: May 2017
• Source: University Hospital, Bonn
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Apathy in dementia prevents successful application of non-pharmacological treatments, accelerates cognitive and functional decline and increases disease-related costs by earlier need for full-time care. Apathy is a distinct entity and occurs independently of other neuropsychiatric syndromes, like depression.

Today, there is no high-level evidence for any effective treatment of apathy in AD. In contrast to other neuropsychiatric syndromes in AD, like psychosis and depression, and despite its high prevalence and clinical relevance, apathy has never been the primary outcome in a clinical trial. Basic and clinical research has provided a distinct model of the pathophysiology of apathy with dopamine and norepinephrine as the key neurotransmitter systems involved. The antidepressant Bupropion is a dopamine and norepinephrine reuptake inhibitor. There is evidence from case-series, that Bupropion reduces apathy in patients with organic brain disorders. This study will test the efficacy and safety of Bupropion in the treatment of apathy in AD in a 12-week multicenter doubleblind placebo controlled trial. Secondary endpoints will be quality of life of patients, caregivers' distress, ability of patients to perform activities of daily living,utilization of healthcare resources by patients and by caregivers, and cognitive functions.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 110
• Est. completion date: July 2014
• Est. primary completion date: July 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 55 Years to 90 Years

Eligibility

Inclusion Criteria:

• Mild to moderate Alzheimer's dementia, male and female (NINCDS/ADRDA criteria)

• Presence of clinically relevant apathy defined by the Neuropsychiatric Inventory (NPI) apathy item (score of >/= 4 points) and the Marin/Starkstein criteria for apathy

• MMSE: 10-25

• Outpatient status, not institutionalized

• Presence of reliable caregiver

• Stable treatment with antidementia drugs for at least three months prior to entry or no treatment with antidementia drugs

Exclusion Criteria:

• Other Dementia (e.g. vascular dementia, Lewy-body dementia, fronto-temporal dementia)

• Presence of a clinically relevant depression defined by either the NPI depression item (score >/= 4 points) or DSM-IV criteria for major depressive episode (with depressed mood)

• Alcoholism and Benzodiazepine addiction

• Current treatment with antipsychotics and antidepressants (including St. John's wart)

• Current treatment with dopaminergic agents or Amantadin

• Current treatment with benzodiazepines

• Current treatment with MAO inhibitor (Bupropion contraindication)

• Known sensibility to Bupropion treatment

• Severe psychiatric disease (including hospitalization) in the last 6 months, suicide attempt, acute psychotic symptoms

• Severe physical illness, that do not allow a participation in a 12-week period of treatment

• Medical history with seizures

• Medical history with tumors of the central nervous system

• Severe craniocerebral injury and medical history with cerebral substance defect

• Clinically relevant renal disease, liver insufficiency

• Simultaneous treatment, which reduces the seizure threshold (e.g. antipsychotics, antidepressants, antimalarial agents, Tramadol, Theophyllin, systemic steroids in higher dose, Chinolone, sedative antihistamines)

• Simultaneous treatment, which is metabolized through Cytochrom P450-Isoenzym 2D6 (e.g. these beta blockers: Metoprolol, Proanolol, Timolol, Carvediol, Nebivolol, Typ-1C-Antiarrhyhtmics for e.g. Propafenon, Flecinid) (except Donepezil and Galantamin)

• Simultaneous treatment with drugs, which may interfere with the metabolization of Bupropion (e.g. Carbamazepin, Phenytoin, Valproat, Ritonavir, Lopinavir)

• Diabetes mellitus, which is therapeutically poorly regulated and treated by medication

• Treatment with stimulants and appetite depressants

• Participation in other clinical trials with in the last 3 months

• Suicidal tendency

• Known lactose intolerance

Related Conditions & MeSH terms

• Alzheimer Disease
• Apathy in Dementia
• Dementia

Intervention

Drug:
• Elontril
flexible dose of Bupropion 150-300 mg
• placebo

Locations

Country	Name	City	State
Germany	Department of Psychiatry, University Bonn	Bonn

Sponsors (16)

Lead Sponsor

Collaborator

University Hospital, Bonn

Charite University, Berlin, Germany, Heidelberg University, Johannes Gutenberg University Mainz, Ludwig-Maximilians - University of Munich, Philipps University Marburg Medical Center, Physician of neurology, psychiatry and psychotherapy Horn, MD; Bad Honnef, Saarland University, Universität Duisburg-Essen, University Hospital Tuebingen, University Medical Center Goettingen, University of Cologne, University of Erlangen-Nürnberg, University of Freiburg, University of Rostock, University of Ulm

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Apathy Evaluation Scale (AES) score		12 weeks
Secondary	NPI total score;NPI caregivers' distress total score;ADCS-ADL; QoL-AD; RUD;ADAScog;MMSE		12 weeks